Can the UK deliver on its ambitions for the Life Sciences sector?

Can the UK deliver on its ambitions for the Life Sciences sector?

Yesterday I attended the excellent PING conference where speakers presented the UK vision for the Life Sciences. This includes seven missions for Healthcare:

  • Improving capabilities in neurodegeneration and dementia
  • Enabling early diagnosis and treatment of cancer
  • Sustaining the UK position in vaccines
  • Reducing mortality from respiratory disease
  • Treatment and prevention of cardiovascular diseases
  • Addressing the biology of aging
  • Increasing the understanding of mental health conditions

These are all important ambitions and the pharmaceutical industry is keen to play its part in achieving them.

However, I have a serious concern that whilst espousing these laudable ambitions the UK is at the same time seriously undermining the MHRA, who will need to play a central role in realising these aims. The MHRA is currently undergoing a major reorganisation, which is cutting 20% of their staff and is resulting in many of their most experienced people departing the Agency. So will the UK actually be able to achieve their Healthcare Mission with a diminished MHRA?

要查看或添加评论,请登录

社区洞察

其他会员也浏览了